Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2015
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
Patients were randomized to either 6 weeks of placebo first followed by 6 weeks of isosorbide mononitrate or 6 weeks of isosorbide mononitrate followed by 6 weeks of placebo.
Vericiguat an investigational oral sGC (soluble guanylate cyclase) stimulator.
The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
The Food and Drug Administration (FDA) recently approved a new 60mg dosage strength for Brilinta to be used in patients with a history of MI beyond the first year.
New Haven Pharmaceuticals announced new data that demonstrates Durlaza (aspirin) extended-release capsules provide sustained antiplatelet control for a full 24-hour period in high-risk patients.
PARADIGM-HF study, which included 8,442-patients, is the largest clinical trial ever conducted in heart failure.
Jardiance, a sodium-glucose co-transporter 2 inhibitor, is indicated as adjunct to diet and exercise to improve glycemic control in adults with T2D.
- Loading...
Want to read more?
Please login or register first to view this content.
